Novartis reported $60.82B in Equity Capital and Reserves for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Alcon AG ALC:SW USD 19.65B 106M
Amgen AMGN:US USD 3.66B 8M
Artemis Alpha ATS:LN GBP 124.1M 35.06M
AstraZeneca AZN:LN USD 35.13B 798M
Bayer BAYN:GR EUR 41.27B 3.25B
Biogen BIIB:US USD 12.78B 903M
Fresenius FRE:GR EUR 21.38B 718M
Fresenius Medical Care FME:GR EUR 15.05B 399.58M
Galapagos GLPG:NA EUR 2.69B 43.45M
Genmab GEN:DC DKK 26.66B 2.18B
Gilead Sciences GILD:US USD 21.21B 128M
GlaxoSmithKline GSK:LN GBP 10.6B 1.45B
Hikma Pharmaceutical HIK:LN USD 2.18B 277M
Lonza Group LONN:SW CHF 10.6B 586M
Merck MRK:GR EUR 28.26B 2.31B
Novartis NOVN:VX USD 60.82B 2.1B
Novartis NVS:US USD 59.34B 1.48B
Orion ORNBV:FH EUR 971.8M 221.9M
Recordati REC:IM EUR 1.61B 116.58M
Regeneron Pharmaceuticals REGN:US USD 22.66B 1.23B
Roche Holding ROG:VX 25.19B 700M